David Teachey

The Impact of Genetic Ancestry on Notch1 Activation and Signaling in T-ALL

National Cancer Institute · R01

Contact PI · $736K · Children's Hosp of Philadelphia

Characterization and Targeting of HSPC-Like Blasts in High-Risk Leukemias

National Cancer Institute · R01

PI · $744.5K · Children's Hosp of Philadelphia

Improving Risk Allocation and Developing Novel Therapies for Children with T-ALL and T-LL

National Cancer Institute · R01

Contact PI · $6.2M · Children's Hosp of Philadelphia

Transcriptomic Molecular Risk Classification for Children with B Cell Acute Lymphoblastic Leukemia

National Cancer Institute · UH2

Contact PI · $350.9K · Children's Hosp of Philadelphia

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Principal investigator · Active not recruiting · Phase 3

National Cancer Institute (NCI)

Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

Principal investigator · Withdrawn · Phase 2

Children's Hospital of Philadelphia

Sirolimus for Autoimmune Disease of Blood Cells

Principal investigator · Completed · Phase 1, Phase 2

Children's Hospital of Philadelphia